Molecular classification does not typically change therapeutic approaches in advanced‐stage (III/IV) patients, so POLE testing may not be needed; however, even in these cases, the presence of a POLE mutation may be indicative of an improved prognosis or response to immunotherapy and a potentially “salvageable” neoplasm and is useful information for the patient. Here, POLE is linked to neoplasm.